Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study
Costa et al • 2016 • J Diabetes Complications.
© 2024 Corcept Therapeutics, Incorporated
Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome.
Yuen et al. • 2015 • Endocr Pract. 2015;21(10):1087-92.
Mifepristone and Cushing syndrome: A commentary.
Kennedy L. • 2015 • Endocr Pract. 2015;21(10):1175-7.
Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study
Morelli et al • 2014 • J Clin Endocrinol Metab.
Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study
Di Dalmazi et al • 2014 • Lancet Diabetes Endocrinol.
Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas
Debono et al • 2014 • J Clin Endocrinol Metab.
A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone.
Fleseriu et al. • 2013 • Endocr Pract. 2013;19(2):313-26.
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.
Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.
Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486).
Chu et al. • 2001 • J Clin Endocrinol Metab. 2001;86(8):3568-73.